F-box protein 33Genealiases: BMND12 · Fbx33 · c14_5247
Q-omics provides the consensus-scored FBXO33 profile across patient tissues and cancer cell-line models. FBXO33 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, FBXO33 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, FBXO33 RNA expression shows 18,974 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where FBXO33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO33 survival associations across molecular data types. FBXO33 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO33 RNA expression–survival associations across cancer types. High FBXO33 expression shows unfavorable associations in UVM and HNSC, but favorable associations in LUAD, MESO, ACC and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for FBXO33 RNA expression.
This table summarizes FBXO33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXO33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO33 shows lower tumor expression in KIRC, THCA, LUSC, LUAD and KIRP and higher tumor expression in HNSC. The KIRC box plot shows higher FBXO33 RNA expression in normal versus tumor tissue (log2 FC = −0.698, t-test p < 0.001).
This table shows molecular features associated with FBXO33 in patient tissues and cancer cell lines. In patient samples, FBXO33 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
